Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022GlobeNewsWire • 03/15/22
Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/22/21
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial ProductsGlobeNewsWire • 11/22/21
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial ProductsGlobeNewsWire • 11/22/21
Kamada Limited (KMDA) CEO Amir London on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/11/21
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development ActivitiesGlobeNewsWire • 08/11/21
Analysts Estimate Kamada (KMDA) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/04/21
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in ChildrenPRNewsWire • 06/02/21
Kamada's (KMDA) CEO Amir London on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/12/21
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development ActivitiesGlobeNewsWire • 05/12/21
Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 TrialBenzinga • 03/31/21
Kamada Announces Top-line Results from its Phase 1/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for Coronavirus Disease (COVID-19)GlobeNewsWire • 03/31/21
Kamada Announces the Closing of the Acquisition of the FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in the U.S.GlobeNewsWire • 03/03/21